AltruBio Inc. to Present Phase 2a Trial Data for Ulcerative Colitis Drug
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AltruBio Inc., a biotech company, announced it will host a virtual Research and Development Day on November 11, 2026. The event will feature key opinion leaders David T. Rubin and Walter Reinisch. They will discuss the current treatment landscape for ulcerative colitis and present data from the Phase 2a ASCEND UC2a trial of ALTB-268.
From manilatimes.net
Why it matters
The presentation covers the efficacy, safety, and tolerability of ALTB-268, which is being evaluated for patients with moderately to severely active ulcerative colitis. The event will also include a discussion of AltruBio’s overall pipeline development.
From manilatimes.net
Who's involved
- Walter ReinischResearcher affiliated with Medical University of Vienna
- David T. RubinKey opinion leader participating in the R&D Day
- Medical University of ViennaAffiliation of Walter Reinisch
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Medical University of Vienna
medical school in Austria
Nothing else this week.
-
David T. Rubin
American gastroenterologist
Nothing else this week.